612 documents

Read All
01:42 , May 4, 2019 |  BioCentury  |  Product Development

How the amyloid hypothesis holds its grip

By now, two things are clear about the amyloid hypothesis of Alzheimer’s disease: one is that the amyloid peptide is somehow involved; the other is that it’s a terrible target. β amyloid has had an...
Read More
01:39 , May 4, 2019 |  BioCentury  |  Product Development

Amyloid: how did we get here and what can we learn?

Unlike any other theory in drug development, the amyloid hypothesis of Alzheimer’s disease has maintained an almost cult-like following, despite two decades littered with a long line of late-stage failures and not a single success....
Read More
23:16 , Apr 24, 2019 |  BC Extra  |  Company News

Biogen reiterates late-stage M&A priority as it calls off planned aducanumab trial

As it contemplates exiting β-amyloid programs, Biogen is prioritizing late-stage M&A to shore up its pipeline and preparing to deliver near-term Phase II readouts from a stable of other non-Alzheimer's disease candidates. The bellwether also...
Read More
14:14 , Mar 25, 2019 |  BioCentury  |  Emerging Company Profile

China Oncology Focus: funding combinations

China Oncology Focus aims to differentiate itself from other Chinese in-licensing plays by leveraging the diversity of its pipeline to develop in-house combination therapies, with its PD-L1 therapy as a backbone. The company is seeking...
Read More
04:15 , Mar 23, 2019 |  BioCentury  |  Product Development

Baby steps beyond beta amyloid

Companies are taking steps -- baby steps -- to test new targets in pathways such as neuroinflammation and neuroprotection as a means to treat Alzheimer’s disease. The failure of aducanumab won’t be the final nail...
Read More
20:10 , Mar 1, 2019 |  BC Week In Review  |  Company News

In latest deal, AbbVie and Voyager seek vectorized antibodies for Parkinson's

AbbVie Inc. (NYSE:ABBV) is expanding its gene therapy footprint through a deal with Voyager Therapeutics Inc. (NASDAQ:VYGR) to develop vectorized antibodies that can cross the blood-brain barrier to target α-synuclein to treat Parkinson's disease. Voyager...
Read More
21:06 , Feb 28, 2019 |  BC Innovations  |  Tools & Techniques

Synuclein PET project

As the Parkinson’s field starts to solve the problem of how to detect toxic α-synuclein in the brain, it’s closing in on imaging agents that could de-risk clinical trials. Phase I data expected this year...
Read More
00:14 , Feb 23, 2019 |  BC Extra  |  Company News

In latest deal, AbbVie and Voyager seek vectorized antibodies for Parkinson's

AbbVie Inc. (NYSE:ABBV) is expanding its gene therapy footprint through a deal with Voyager Therapeutics Inc. (NASDAQ:VYGR) to develop vectorized antibodies that can cross the blood-brain barrier to target α-synuclein to treat Parkinson's disease. Voyager...
Read More
23:50 , Feb 21, 2019 |  BC Week In Review  |  Company News

University of Dundee, Takeda partner on tau pathologies

The Drug Discovery Unit of the University of Dundee (Dundee, U.K.) partnered with Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) to develop small molecules that prevent the spread tau pathology from diseased to healthy cells to treat...
Read More
00:23 , Feb 15, 2019 |  BC Innovations  |  Product R&D

A bug about Alzheimer’s

Cortexyme Inc. believes it has connected the dots between Alzheimer’s and gum disease, outlining a path from the bacteria that cause periodontitis to chronic brain infection with hallmarks of AD. But in a field that...
Read More